Despite differences in the phamacokinetics of 25-hydroxycholecalciferol (25(OH)D 3 ) and 25-hydroxyergocalciferol (25(OH)D 2 ) in man, the effects of these and their 1α-hydroxylated forms (1,25(OH) 2 D 3 and 1,25(OH) 2 D 2 ) on cellular activity of vitamin D-responsive cells have hardly been compared. We studied differences in the effects of these metabolites on cell number, gene transcription, protein expression and mineralisation of cultured human bone marrow-derived stromal cells (hBMSC) and rapidly mineralising mouse 2T3 osteoblasts. 50-1000 nM 25(OH) and 0.05-10 nM 1,25(OH) 2 metabolites were used. At high concentrations, 25(OH)D 2 /D 3 and 1,25(OH) 2 D 2 /D 3 suppressed cell number in both human and mouse cells. The suppression was greater with cholecalciferol (D 3 ) metabolites than with those of ergocalciferol (D 2 ). In both cell types, 25(OH)D 2 and 25(OH)D 3 increased the expression of osteopontin, osteocalcin, collagen-1, receptor activator of nuclear factor kappa-B ligand, vitamin D receptor, CYP24A1 and CYP27B1 genes. Whereas there was little or no difference between the effects of 25(OH)D 2 and 25(OH)D 3 in hBMSCs, differences were observed in the magnitude of the effects of these metabolites on the expression of most studied genes in 2T3 cells. Alkaline phosphatase (ALP) activity was increased by 25(OH) D 2 /D 3 and 1,25(OH) 2 D 2 /D 3 in hBMSC and 2T3 cells, and the increase was greater with the D 3 metabolites at high concentrations. In hBMSCs, mineralisation was also increased by 25 (OH)D 2 /D 3 and 1,25(OH) 2 D 2 /D 3 at high concentrations, with D 3 metabolites exerting a greater influence. In 2T3 cells, the effects of these compounds on mineralisation were stimulatory at low concentrations and inhibitory when high concentrations were used. The suppression at high concentrations was greater with the D 3 metabolites. These findings suggest that there are differences in the effects of 25-hydroxy and 1α,25(OH) 2 metabolites of D 3 and D 2 on human preosteoblasts and mouse osteoblasts, with the D 3 metabolites PLOS ONE |
Introduction
Vitamin D (vit D) regulates bone function and its deficiency is associated with bone loss [1, 2] . Vit D receptors (VDR) are present in almost all human cells, and the list of roles and functions of vit D has been expanding [3] . Osteoblasts, too, express VDR, although exactly how 1α,25-dihydroxycholecalciferol (1,25(OH) 2 D 3 ) and 1α,25-dihydroxyergocalciferol (1,25 (OH) 2 D 2 ) act on these cells to regulate bone metabolism is not fully understood [4] . Osteoblasts differentiate from bone marrow-derived stromal cells (BMSCs) through several welldefined stages that include proliferation, maturation and mineralisation [5] . During the final extracellular matrix formation step, some osteoblasts get embedded in osteoid as osteocytes [6] . 1,25(OH) 2 D 3 promotes differentiation of human BMSCs into osteoblasts, inhibits cell proliferation, and stimulates mineralisation in both human and mouse osteoblast cells [7] [8] [9] [10] . Some of these effects are mediated through LRP5 and the Wnt signalling pathway [11, 12] , and the stimulation of mineralisation is partly secondary to an increase in osteoblastic alkaline phosphatase (ALP) activity [13] . The 1α,25-hydroxylated metabolites induce the expression of osteoblast signature genes, including collagen type-I (col1a), osteocalcin (ocn), osteopontin (opn), osteoprotegerin (opg), receptor activator of nuclear factor kappa-B ligand (rankl), vdr [10, 14] . Thus, formation of COL1a and non-collagenous proteins, such as OCN and OPN, are stimulated by 1,25(OH) 2 D 3 , and osteoclastogenesis is inhibited by an increase in OPG, which binds RANKL and prevents its interaction with RANK on osteoclast precursors [8] . Osteoblasts also possess CYP27B1 enzyme, which 1α-hydroxylates 25-hydoxycholecalcifeol (25(OH) D 3 ) and 25-hydoxyergocalcifeol (25(OH)D 2 ) into 1,25(OH) 2 D 3 and 1,25(OH) 2 D 3 , as well as 1α,25-dihydroxycholecalciferol 24-hydroxylase, CYP24A1. Osteoblasts are therefore capable of responding locally to 25-(OH)D and produce metabolites that act in an autocrine fashion [14, 15] .
Patients with vit D deficiency carry a risk of reduced bone mineral density and developing osteoporosis. With the recognition that large portions of populations living at high latitudes are deficient in vit D [16] [17] [18] , a need to identify and treat the deficiency has increasing been realised. For the treatment, it has been generally assumed that the two prescribed forms of vit D, cholecalciferol (D 3 ) and ergocalciferol (D 2 ), have equal potencies. However, this has been questioned [19, 20] . A few studies in humans have shown that lower circulating concentrations of 25(OH)D are achieved as a result of the administration of D 2 compared with D 3 [21, 22] . Other studies have shown a lower binding to vit D-binding protein and a higher clearance rate for D 2 metabolites compared with those of D 3 [23, 24] , and differences in the effects of active D 2 and D 3 metabolites on plasma calcium and bone mineral content have been observed [25, 26] [30] , and differences in the effects of 1α-cholecalciferol and 1α-ergocalciferol were shown in rat intestinal calcium absorption, and osteoclast numbers and activity [31, 32] . As for osteoblasts, to the best of our knowledge, no study has compared their response to 25(OH) or 1,25(OH) 2 metabolites of D 2 and D 3 . Therefore, we have undertaken a comparison of the effects and potencies of 25(OH) and 1,25(OH) 2 metabolites of D 2 and D 3 on osteoblast cell number, cellular activity and mineralisation. For this, we have used two very distinct cell types: primary human bone marrowderived stromal cells (hBMSC) and mouse 2T3 osteoblastic cell line. Human BMSCs are at the initial stage of differentiation, and require osteogenic factors and time to develop into pre-and full osteoblasts. Based on our unpublished data, these cells require a period of 4 weeks to become responsive and to begin to mineralise, whereas murine 2T3 cells are primary murine osteoblasts that have been immortalised using SV40 large T antigen on the BMP2 promoter and that respond rapidly to matrix maturation and mineralisation signals.
Material and Methods

Cell culture
Human BMSCs were derived from discarded bone material from patients undergoing total hip replacement. The use of bone material was approved by the University of Oxford Musculoskeletal Biobank Ethical Committee in compliance with Human Tissue Act ethical guidelines, and was after obtaining written, informed consent from patients [33] . Human BMSCs were cultured and studied at passage 1-2 in α-Modified Eagle's Minimum Essential Medium (αMEM, Lonza), supplemented with 10% heat-inactivated foetal bovine serum (HI-FBS; Lonza, UK), L-glutamine (2mM), ribonucleosides, penicillin and streptomycin (100U/ml).
Murine 2T3 pre-osteoblast cells were kind donations from Professor Stephen E. Harris (University of Texas, San Antonio, USA) and have been characterized previously [34] . These cells were isolated and cloned from transgenic mice, containing SV-40 large T antigen, driven by a BMP-2 promoter. When treated with osteogenic supplements, these cells mineralize and form bone matrix, expressing osteoblastic markers. The cells were plated at 1 x 10 6 per T-150 flasks in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated foetal bovine serum (HI-FBS; Lonza, UK), penicillin (100 U/ml), streptomycin (100 U/ml) and L-glutamine (Invitrogen, 2 mM) in a standard humidified incubator at 37˚C and 5% CO 2 To induce hBMSCs differentiation, these cells were plated in αMEM plus 10% HI-FBS to reach confluency, then supplemented with osteogenic medium (OSM, 10% HI-FBS, 10 mM β-glycerol 2-phosphate disodium salt and 50 μg/ml L-ascorbic acid (Sigma Aldrich, UK) and the addition of 10 nM dexamethasone. To promote differentiation of mouse 2T3 cells at confluency, the medium was changed to OSM. Cells were cultured in replicates in OSM in the presence of absence of various concentrations of 25(OH)D 2 /D 3 (50-1000 nM) or 1,25(OH) 2 D 2 /D 3 (0.05-10 nM) in ethanol as vehicle (total added volume was <1% of the culture medium volume). OSM media containing the vit D metabolites were changed every other day prior to RNA and protein extraction or until mineralisation was assessed.
Cell number
Mouse 2T3 and hBMSCs were seeded in multiple 96-well plates at 5x10 3 and lysed in 100 μl radioimmunoprecipitation assay buffer containing protease inhibitor (RIPA-PI; Sigma). Cell lysates were sonicated for 15 sec and total protein content was measured by bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, UK). For each treated condition, ALP activities (pmol substrate/μg protein) of cell lysates were determined fluorometrically using fluorescent substrate 4-methylumbelliferyl phosphate (4-MUP; Sigma) as previously described [35] . Briefly, 10 μl of each cell lysate was incubated with 100 μl of freshly made 4MUP (0.16 mM in 50 mM Tris pH 6.0) substrate in white 96-well plates (NUNC) for 45 min in the dark at 37˚C, followed by the addition of 100 μl of 0.6M Na 2 CO 3 to stop the reaction. Fluorescence was measured at 360 nm excitation, 450 nm emission and 435 nm cut-off wavelength using a BMG Optima FluoSTAR plate reader (BMG LABTECH, Germany). ALP activities were calculated from standard curves of 0-20,000 pmol 4-methylumbelliferone (4MU), and values were normalised against the total protein content of each relevant well or treatment. and 260/230 ratios of !2 were used for further analysis. The integrity of total RNA purified with Qiagen RNeasy kit was also assessed using 1.5% agarose gel electrophoresis and ethidium bromide staining. A total of 2 μg from each extract was treated with RNase-free DNase I (Thermo Scientific, UK) for 30 min at 37˚C. Removal of genomic DNA was terminated by further heat inactivation with 100mM EDTA at 65˚C for 10 mins. First strand cDNA synthesis of template RNA extracts was performed using a Veriti 96 well Thermal Cycler (Applied Biosystems, UK) using BIO-RAD iScript Reverse Transcription Supermix in a final reaction volume of 40 μl according to the manufacturer's instruction.
Western blots
RT-PCR was performed using a ViiA7 system (Applied Biosytems, UK) with commercially available lyophilized Quanititect Qiagen primers; col1, opn, ocn, opg, rankl, vdr, cyp27b1, cyp24a1. One μl of one-twentieth dilutions of templates were used in a total volume of 10 μl reaction in 384 well plates (Applied Biosystems, UK) by 2-step cycling (polymerase activation at 95˚C for 2 min, 40 cycles of template denaturation at 95˚C for 5 sec, primer annealing and extension at 65˚C for 30 sec) using SYBR green Master Mix (BIOLINE; SensiFAST SYBR LoRox Kit). The C t values for treated samples were normalised to housekeeping genes gapdh and 18S and the relative expressions were calculated using ΔΔ C t with amplification and accuracy of 98-100%.
Mineralisation
Human BMSCs were cultured at 1x10 4 
Statistical analysis
All experiments were carried out at least in triplicates and the mean ± SEM was calculated. Statistical analyses were carried out using SPSS version 11.0 for windows (SPSS Inc., Chicago, IL, USA). Effects of treatments were compared by Kruskal-Wallis one-way analysis of variance (ANOVA), with differences between treatments assessed using Bonferroni error protection for multiple comparisons. A P value of <0.05 was regarded to indicate a significant difference. Fig 1A) . Only a small decrease in hBMSC numbers as a result of treatment with the highest dose of 1,25(OH) 2 D 3 (1 nM) was observed (P<0.05; Fig 1B) . When mouse 2T3 osteoblasts were exposed to 25(OH)D 2 , cell numbers were reduced at doses of 500 nM and 1000 nM (P<0.05 and P<0.01, respectively; Fig 1C) . A decrease in 2T3 cell numbers was also observed with 25(OH)D 3 at doses of 500 nM and 1000 nM (P<0.001 for both concentrations; Fig 1C) . The magnitude of the decrease was greater with 25(OH)D 3 Fig 1C) . In 2T3 cells, whereas 1,25(OH) 2 D 3 at !0.5 nM concentrations reduced cell numbers significantly (P<0.001; Fig 1D) , 1,25(OH) 2 D 2 had no such effects, and, if anything, showed a tendency to increase cell numbers only at 0.2 nM (P<0.01; Fig 1D) .
Results
Human BMS and mouse cell numbers
ALP in hBMSCs and mouse osteoblasts
In hBMSCs, ALP activity increased after 7 days of treatment with 500-1000 nM 25(OH)D 2 and 25(OH)D 3 compared with controls (P<0.001; Fig 2A) . After a similar period of treatment with 1,25(OH) 2 D 2 and 1,25(OH) 2 D 3 but only at a dose of 10 nM, ALP activity also increased compared with controls (P<0.001; Fig 2B) . Human BMSCs displayed a differential response to D 2 versus D 3 metabolites, with greater potencies observed in the case of 25(OH)D 3 (P<0.05 at 500 nM and P<0.01 at 1000 nM; Fig 2A) and 1,25(OH) 2 D 3 (P<0.01 for 1 nM; Fig 2B) .
At 100-500 nM concentrations, both 25(OH)D 2 and 25(OH)D 3 also increased ALP activity in 2T3 cells after 24 h of treatment (P<0.001; Fig 2C-2E Fig 3A) , and had comparable effects in up-regulating transcriptions of rankl (P<0.0001; Fig 3B) , col1a (P<0.01; Fig 3C) , opn (P<0.001; Fig 3D) , vdr (P<0.001; Fig  3F) , cyp24a1 (P<0.05 for D 2 and P<0.01 for D 3 ; Fig 3G) and cyp27b1 (P<0.05; Fig 3H) compared with controls. 25(OH)D 2 was more potent than 25(OH)D 3 in up-regulation of ocn in hBMSCs (P<0.01; Fig 3E) .
When murine 2T3 osteoblasts were treated with 200 nM of 25(OH)D 2 or 25(OH)D 3 for 24 h in osteogenic media, there was an increase in the transcription of opg (P<0.01 for D 3 ; Fig  4A) , rankl (P<0.001 for both metabolites; Fig 4B) , col1a (P<0.001 for both metabolites; Fig 4C) , opn (P<0.001 for both metabolites; Fig 4D) 
Western blot
In hBMSCs, the expression of VDR, CYP27B1, OCN and CYP24A1 proteins appeared to be up-regulated to a greater extent in response to the addition of 1000 nM 25(OH)D 3 than 25 (OH)D 2 ( Fig 3I) . When hBMSCs were treated with 10 nM 1,25(OH) 2 D 2 or 1,25(OH) 2 D 3, both metabolites up-regulated VDR, OCN and CYP24A1 equally (Fig 3I) . Neither metabolite had any effects on CYP24A1. 1,25(OH) 2 D 3 appeared more potent that 1,25(OH) 2 D 2 in up-regulating OPN protein in hBMSCs (Fig 3I) .
In 2T3 cells treated with 25(OH)D 2 or 25(OH)D 3 , there were moderate increases in VDR, CYP27B1, OPN and OCN at 200 nM (Fig 4I) . However, a reduction of these proteins was observed with 500 nM of both 25(OH)D 2 and 25(OH)D 3 , with the latter being more potent in this reduction (Fig 4I) . There were dose-dependent increases in VDR, OPN and OCN protein expression in response to 1,25(OH) 2 D 2 and 1,25(OH) 2 D 3 , where 0.2-0.5 nM 1,25(OH) 2 D 2 elicited the greatest response (Fig 4J) . 
Discussion
To the best of our knowledge, this is the first study that has compared the effects of 25(OH) or 1,25(OH) 2 metabolites of D 2 and D 3 on osteoblasts. Unlike previous studies that have employed pharmacologically high concentrations of 25(OH) and 1,25(OH) 2 metabolites, we used concentrations that were generally much lower and more physiological [4, 7, 9, 15] . Differences in the effects of these metabolites on osteoblastic cells from human and mouse that were also very distinct in their stage of differentiation were studied. Most previous studies have shown the effects of vit D metabolites on osteoblast proliferation to be inhibitory [14, 36, 37] .
In hBMSCs, 25(OH)D 3 had a greater inhibitory effect on cell number than 25(OH)D 2 , and with 1,25(OH) 2 metabolites, an inhibition was seen only with 1,25(OH) 2 D 3 at a concentration of 1000 pmol/L. We also found both 25(OH)D and 1,25(OH) 2 D metabolites to inhibit increasing 2T3 cell number, and the suppressive effects to be greater with the D 3 metabolites. A recent study on human osteoblasts have shown 1,25(OH) 2 D 3 metabolite to decrease cell proliferation, but only at a pharmacologically high concentration of 100 nmol/L administered over 3 days [15] . Our data show that over a period of 24 h, some stasis in cell number, albeit small, appear to be present at lower vit D metabolite concentrations, particularly with those of D 3 . Such antiproliferative effects are achieved by cell cycle arrest, with the effects of 25(OH)D presumably mediated through the activity of CYP27B1 and the generation of 1,25(OH) 2 [38] .
During the differentiation of hBMSCs into osteoblasts, their VDR expression increases [39] . Our observations on VDR gene and protein expression lend support to this, particularly in relation to stimulation by 25(OH)D metabolites, with 25(OH)D 3 having a greater effect on the VDR protein. Activated VDR acts as a transcription factor for osteoblast signature genes, Comparison of the Effects of Vitamin D2 and D3 Metabolites on Human and Mouse Osteoblasts and in hBMSCs, active vit D metabolites stimulate the manufacture of bone matrix proteins that include Col1, OCN and OPN, and increase ALP production that promotes mineralisation [7, 13, 40, 41] . Our data in hBMSCs are consistent with such previous findings, with both 25 (OH)D metabolites increasing the transcription of col1, ocn and opn matrix protein genes, as well as that of opn, rankl, and cyp24a1 and cyp27b1. Our data showed a greater effect of 25 (OH)D 3 than 25(OH)D 2 in increasing the manufacture of ALP, OCN, CYP24A1 and CY27B1 proteins.
It is unclear why 1,25(OH) 2 metabolites did not affect hBMSC cell number or stimulate VDR, CYP24A1 and CYP27B1 as much as 25(OH) metabolites did. Whether this may be related to higher 1,25(OH) 2 D concentrations produced at cellular level from nM range of 25 (OH)D used is unknown, although some previous findings seem to suggest this [38] . An increase in CYP27B1 increases 1,25(OH) 2 However, previous data in some murine osteoblasts have shown that, unlike its effects on human cells, vit D metabolites appear to inhibit differentiation and mineralisation, although studies on murine ALP and Col1 show some conflicting data [9, [48] [49] [50] [51] . Our observations on 2T3 mineralisation indicate a bimodal concentration effect of vit D metabolites in these cells. Thus, there was an increase in mineralisation at low vit D metabolites concentrations, but the These findings indicate that cell activity can change significantly over time under the influence of active vit D metabolites. In that respect, two different concentrations of a vit D metabolite may be able to bring about two patterns of change in cell activity that are out of synch with one another during their time course. For this reason, it is possible that some of the conflicting differences in the expression of a particular protein seen with D 3 and D 2 metabolites may be secondary to a greater potency of one metabolite that imposes a shift in the time course of change in that protein. The data on such a protein can then become conflicting when there is both an increase and a decrease in protein expression over a time course. Such apparent conflicts may be possible in our study as we assessed gene expression over long periods of 1 and 14 days of treatment of 2T3 and hBMS cells, respectively. Furthermore, the effects of vit D metabolites on osteoblasts are known to be influenced by other factors such as calcium concentrations [52] . How these other factors change over time is unknown, but they can potentially add further complexity to the dynamics of the effects of vit D metabolites that may possess different potencies.
Overall, the data from this study suggest that in general vit D 3 metabolites appear to elicit a greater influence on both hBMSC and mouse 2T3 cells. These greater effects appear not to be universal, but seem to be more pronounced in some major aspects of osteoblast function, particularly in changing cell number and in increasing ALP and mineralisation. The only greater influences of 25(OH)D 2 that we found were on OCN expression in hBMSCs and on CYP27B1 expression in 2T3 calls. Assuming that the effects of 25(OH)D are mostly mediated through the generation of its α-hydroxylated compound by CYP27B1, as well as the metabolism of 25 (OH)D and 1,25(OH) 2 D by CYP24A1, consideration must be given to the possibility that the velocity and the Km of these enzymes may differ significantly for 25(OH)D 2 and 25(OH)D 3 .
Furthermore, some of the differences in the effects of vit D 3 metabolites on osteoblast proliferation and function appear to be also time-and cell-type-dependent [10] . The same may be true for the effects of D 2 metabolites. As with others, we have observed that the direction and the effects of vit D metabolites can differ sufficiently in the two osteoblastic cell types studied so as to preclude the use of mouse model to derive knowledge about human cells. In some respects, the data on mouse osteoblasts may in fact be even misleading in predicting the behaviour of human cells. However, human osteosarcoma cell lines display similarly diverse responses, with neither MG63 nor SaOS2 cell lines responding to the same dose and range of vitamin D as primary hBMSCs with either ALP activity or mineralisation (S1 Fig in supporting  information) . In conclusion, our data on osteoblasts add significant weight to some previous findings that D 2 may not have the same potency and may not elicit the same physiological effect as D 3 . If corroborated by further future studies, these findings would underline a need to assess differences in long-term physiological effects of the two vitamins in human subjects. Evidence gathered from such studies may prove to have implications for prescribing D 2 preparations in clinical practice. 
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